Logo image of BBIO

BRIDGEBIO PHARMA INC (BBIO) Stock Price, Quote, News and Overview

NASDAQ:BBIO - Nasdaq - US10806X1028 - Common Stock - Currency: USD

35.79  -1.15 (-3.11%)

BBIO Quote, Performance and Key Statistics

BRIDGEBIO PHARMA INC

NASDAQ:BBIO (5/7/2025, 1:48:00 PM)

35.79

-1.15 (-3.11%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High39.54
52 Week Low21.62
Market Cap6.80B
Shares189.88M
Float156.22M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-30 2025-07-30/bmo
IPO06-27 2019-06-27


BBIO short term performance overview.The bars show the price performance of BBIO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

BBIO long term performance overview.The bars show the price performance of BBIO in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300 400

The current stock price of BBIO is 35.79 USD. In the past month the price increased by 20.44%. In the past year, price increased by 26.94%.

BRIDGEBIO PHARMA INC / BBIO Daily stock chart

BBIO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.46 335.33B
AMGN AMGEN INC 13.27 148.10B
GILD GILEAD SCIENCES INC 12.81 123.45B
VRTX VERTEX PHARMACEUTICALS INC N/A 113.04B
REGN REGENERON PHARMACEUTICALS 12.72 60.84B
ARGX ARGENX SE - ADR 328.21 38.08B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 35.76B
ONC BEIGENE LTD-ADR N/A 25.03B
BNTX BIONTECH SE-ADR N/A 22.59B
NTRA NATERA INC N/A 21.63B
SMMT SUMMIT THERAPEUTICS INC N/A 17.90B
BIIB BIOGEN INC 7.41 17.18B

About BBIO

Company Profile

BBIO logo image BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 725 full-time employees. The company went IPO on 2019-06-27. The company discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. The company also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

Company Info

BRIDGEBIO PHARMA INC

3160 Porter Dr., Suite 250

Palo Alto CALIFORNIA 94301 US

CEO: Neil Kumar

Employees: 728

BBIO Company Website

BBIO Investor Relations

Phone: 16503919740

BRIDGEBIO PHARMA INC / BBIO FAQ

What is the stock price of BRIDGEBIO PHARMA INC today?

The current stock price of BBIO is 35.79 USD. The price decreased by -3.11% in the last trading session.


What is the ticker symbol for BRIDGEBIO PHARMA INC stock?

The exchange symbol of BRIDGEBIO PHARMA INC is BBIO and it is listed on the Nasdaq exchange.


On which exchange is BBIO stock listed?

BBIO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BRIDGEBIO PHARMA INC stock?

24 analysts have analysed BBIO and the average price target is 60.44 USD. This implies a price increase of 68.86% is expected in the next year compared to the current price of 35.79. Check the BRIDGEBIO PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BRIDGEBIO PHARMA INC worth?

BRIDGEBIO PHARMA INC (BBIO) has a market capitalization of 6.80B USD. This makes BBIO a Mid Cap stock.


How many employees does BRIDGEBIO PHARMA INC have?

BRIDGEBIO PHARMA INC (BBIO) currently has 728 employees.


What are the support and resistance levels for BRIDGEBIO PHARMA INC (BBIO) stock?

BRIDGEBIO PHARMA INC (BBIO) has a support level at 33.5 and a resistance level at 38.58. Check the full technical report for a detailed analysis of BBIO support and resistance levels.


Is BRIDGEBIO PHARMA INC (BBIO) expected to grow?

The Revenue of BRIDGEBIO PHARMA INC (BBIO) is expected to grow by 12.64% in the next year. Check the estimates tab for more information on the BBIO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BRIDGEBIO PHARMA INC (BBIO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BRIDGEBIO PHARMA INC (BBIO) stock pay dividends?

BBIO does not pay a dividend.


When does BRIDGEBIO PHARMA INC (BBIO) report earnings?

BRIDGEBIO PHARMA INC (BBIO) will report earnings on 2025-07-30, before the market open.


What is the Price/Earnings (PE) ratio of BRIDGEBIO PHARMA INC (BBIO)?

BRIDGEBIO PHARMA INC (BBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.77).


What is the Short Interest ratio of BRIDGEBIO PHARMA INC (BBIO) stock?

The outstanding short interest for BRIDGEBIO PHARMA INC (BBIO) is 14.25% of its float. Check the ownership tab for more information on the BBIO short interest.


BBIO Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to BBIO. When comparing the yearly performance of all stocks, BBIO is one of the better performing stocks in the market, outperforming 91.76% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

BBIO Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to BBIO. BBIO has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BBIO Financial Highlights

Over the last trailing twelve months BBIO reported a non-GAAP Earnings per Share(EPS) of -3.77. The EPS decreased by -17.08% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -58.28%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-340%
Sales Q2Q%-44.76%
EPS 1Y (TTM)-17.08%
Revenue 1Y (TTM)2285.27%

BBIO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to BBIO. The Buy consensus is the average rating of analysts ratings from 24 analysts.

For the next year, analysts expect an EPS growth of -23.91% and a revenue growth 12.64% for BBIO


Ownership
Inst Owners78.13%
Ins Owners2.41%
Short Float %14.25%
Short Ratio7.21
Analysts
Analysts81.67
Price Target60.44 (68.87%)
EPS Next Y-23.91%
Revenue Next Year12.64%